Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Synthetic Stereoisomers of Hyperzine A for Protection Against Chemical Warfare Agents (CWA), CWA-Induced Seizures, and Other Neurological Seizures, 66603 [E8-26719]

Download as PDF Federal Register / Vol. 73, No. 218 / Monday, November 10, 2008 / Notices Division, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313–1450. Written comments and recommendations for the proposed information collection should be sent on or before December 10, 2008 to Nicholas A. Fraser, OMB Desk Officer, via e-mail at Nicholas_A._Fraser@omb.eop.gov, or by fax to 202–395–5167, marked to the attention of Nicholas A. Fraser. Dated: November 3, 2008. Susan K. Fawcett, Records Officer, USPTO, Office of the Chief Information Officer, Customer Information Services Group, Public Information Services Division. [FR Doc. E8–26697 Filed 11–7–08; 8:45 am] BILLING CODE 3510–16–P DEPARTMENT OF DEFENSE Office of the Secretary Defense Health Board (DHB) Meeting Department of Defense (DoD). Notice of meeting. AGENCY: jlentini on PROD1PC65 with NOTICES ACTION: SUMMARY: Pursuant to the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix as amended), the Sunshine in the Government Act of 1976 (5 U.S.C. 552b, as amended), and 41 CFR102–3.150, and in accordance with section 10(a)(2) of Public Law, the following meeting of the Defense Health Board is announced: DATES: November 20, 2008 (9 a.m.–12 p.m. EST (Open Session)). ADDRESSES: Sheraton Crystal City, 1800 Jefferson Davis Highway, Arlington, VA 22202. FOR FURTHER INFORMATION CONTACT: Colonel Roger L. Gibson, Executive Secretary, Defense Health Board, Five Skyline Place, 5111 Leesburg Pike, Suite 810, Falls Church, Virginia 22041–3206, (703) 681–8448, EXT. 1228, Fax: (703) 681–3317, roger.gibson@ha.osd.mil. Additional information, agenda updates, and meeting registration are available online at the Defense Health Board Web site, http://www.ha.osd.mil/dhb. The public is encouraged to register for the meeting. If special accommodations are required to attend (sign language, wheelchair accessibility) please contact Ms. Lisa Jarrett at (703) 681–8448 ext. 1280 by November 12, 2008. Written statements may be mailed to the above address, e-mailed to dhb@ha.osd.mil or faxed to (703) 681–3317. SUPPLEMENTARY INFORMATION: Purpose of the Meeting: The purpose of the meeting is to address pending issues before the Board and deliberate in VerDate Aug<31>2005 16:09 Nov 07, 2008 Jkt 217001 open session the status of reports by subcommittees. Agenda: On November 20, 2008 the Board will receive updates and deliberate upon the findings from the following Defense Health Board (DHB) subcommittees: Military Occupational & Environmental Health and Medical Surviellance Subcommitee, the DHB Review Panel for the Establishment of the Joint Pathology Center, DHB Review Panel on the Department of Defense Biological Defense Research Program, and the National Capital Region Base Realignment And Closure (NCR BRAC) Advisory Panel. Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102–3.140 through 102–3.165 the Defense Health Board invites members of the public to attend the meeting from 9 a.m. to 12 Noon Eastern Standard Time on November 20, 2008. As an alternative to being present at this meeting, the public may access the DHB Web site to view the slides presented in real time at this location: http://www.health.mil/dhb/ default.cfm and listen to the audio by dialing the following toll-free phone number: 1–877–771–5191. Any member of the public wishing to provide input to the Defense Health Board may submit a written statement in accordance with 41 CFR 102– 3.140(C) and section 10(a)(3) of the Federal Advisory Committee Act, and the procedures described in this notice. Written statement should not be longer than two type-written pages and must address the following detail: The issue, discussion, and a recommended course of action. Supporting documentation may also be included as needed to establish the appropriate historical context and to provide any necessary background information. Individuals desiring to submit a written statement may do so through the Board’s Designated Federal Officer at the address detailed above at any point. However, if the written statement is not received at least 10 calendar days prior to the meeting, which is subject to this notice, then it may not be provided to or considered by the Defense Health Board until the next open meeting. The Designated Federal Officer will review all timely submissions with the Defense Health Board Chairperson, and ensure they are provided to members of the Defense Health Board before the meeting that is subject to this notice. After reviewing the written comments, the Chairperson and the Designated Federal Officer may choose to invite the submitter of the comments to orally present their issue during an open portion of this meeting or at a future meeting. PO 00000 Frm 00014 Fmt 4703 Sfmt 4703 66603 The Designated Federal Officer, in consultation with the Defense Health Board Chairperson, may, if desired, allot a specific amount of time for members of the public to present their issues for review and discussion by the Defense Health Board. Dated: November 3, 2008. Patricia L. Toppings, OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. E8–26712 Filed 11–7–08; 8:45 am] BILLING CODE 5001–06–P DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Synthetic Stereoisomers of Hyperzine A for Protection Against Chemical Warfare Agents (CWA), CWA-Induced Seizures, and Other Neurological Seizures Department of the Army, DoD. Notice. AGENCY: ACTION: SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/ 104,388 entitled ‘‘Synthetic Stereoisomers of Hyperzine A for Protection Against Chemical Warfare Agents (CWA), CWA-Induced Seizures, and other Neurological Seizures,’’ filed October 10, 2008. The United States Government, as represented by the Secretary of the Army, has rights in this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention comprises pre and/or post exposure treatment of a patient with [+]Huperzine A for chemical warfare nerve agent or organophosphate induced seizure/status epilepticus and neuropathology. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. E8–26719 Filed 11–7–08; 8:45 am] BILLING CODE 3710–08–P E:\FR\FM\10NON1.SGM 10NON1

Agencies

[Federal Register Volume 73, Number 218 (Monday, November 10, 2008)]
[Notices]
[Page 66603]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-26719]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Provisional Patent Application Concerning Synthetic 
Stereoisomers of Hyperzine A for Protection Against Chemical Warfare 
Agents (CWA), CWA-Induced Seizures, and Other Neurological Seizures

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Announcement is made of the availability for licensing of the 
invention set forth in U.S. Provisional Patent Application Serial No. 
61/104,388 entitled ``Synthetic Stereoisomers of Hyperzine A for 
Protection Against Chemical Warfare Agents (CWA), CWA-Induced Seizures, 
and other Neurological Seizures,'' filed October 10, 2008. The United 
States Government, as represented by the Secretary of the Army, has 
rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention comprises pre and/or post 
exposure treatment of a patient with [+]-Huperzine A for chemical 
warfare nerve agent or organophosphate induced seizure/status 
epilepticus and neuropathology.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
 [FR Doc. E8-26719 Filed 11-7-08; 8:45 am]
BILLING CODE 3710-08-P